PLYX Stock Summary and Trading Ideas (Polaryx Therapeutics | NASDAQ:PLYX)

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Polaryx Therapeutics trades on the NASDAQ stock market under the symbol PLYX.

As of September 11, 2026, PLYX stock price climbed to $2.01 with 14,219 million shares trading.

PLYX has a beta of 0.47, meaning it tends to be less sensitive to market movements. PLYX has a correlation of 0.00 to the broad based SPY ETF.

PLYX has a market cap of $100.19 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that PLYX belongs to (by Net Assets): VTI, VXF.

PLYX support price is $1.85 and resistance is $2.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLYX shares will trade within this expected range on the day.